Scrapped CGM sensors stolen, sold to patients—Dexcom pledges to hold thieves accountable
Dexcom has announced that certain lots of its G7 all-in-one continuous glucose monitoring (CGM) sensors were stolen by a third party and are now being sold into the market.
The devices were originally designated as scrap and set aside to be destroyed. However, they were stolen instead and are now starting to be used by patients—patients who are unaware they are using stolen sensors that should not be used.
The U.S. Food and Drug Administration (FDA) helped Dexcom spread the word about this incident by sharing the company’s announcement.
“Nothing matters more to Dexcom than the safety of our users and maintaining the trust of the diabetes community,” Jake Leach, president and CEO of Dexcom, explained in the statement. “We are treating this matter with the utmost seriousness and are working closely with regulators and other authorities to ensure user safety, determine exactly how this product was stolen and hold the perpetrators fully accountable for their crimes.”
Dexcom has warned that these stolen devices should not be used. Patients concerned they may have one of the stolen Dexcom G7 sensors can visit this website.
No severe adverse events have been linked to these stolen Dexcom G7 sensors. However, the company warned that one lot—1725204004—includes devices that are not properly sterilized and could lead to a skin infection. Another lot—1725069002—includes devices that had an elevated internal testing failure rate.
Click here to read more details on the FDA’s website.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.